Facebook Twitter Linkedin

Research & Development

Grants and Contracts update

NIAID Adjuvant Development Contract: Development of TRAC-478: A Synthetic Dual TLR Adjuvant Combination System; 9/30/2020 – 9/29/2023

NIAID Adjuvant Development Contract: Boston Children’s Hospital; 9/30/2020 – 9/29/2023

SBIR Phase I Adjuvant Discovery Contract: New small molecule TLR4 agonists for the treatment of Allergic Rhinitis; 8/2018 – 8/2020

R01 Grant Subaward: Immunization against filamentous bacteriophages to prevent bacterial infection; 6/8/2018 – 2/31/2023

SBIR Phase II – Upper Respiratory Tract Infections; 9/1/2019 – 08/31/2121

3 Adjuvant Discovery Sub-Contracts (UM/Duke University, Oregon Health Sciences University, Boston Children’s Hospital); 9/30/2019 – 9/29/2024

Dept. of Defense MRMC Grant for Berkeleylactone development (joint with UM); 2020-2022

Opioid Vaccine Contracts: University of Montana & Boston Children’s Hospital (Subawards to Inimmune); June 2020-May 2022

SBIR Phase II Contract for multi-component adjuvant formulations; September 2020-August 2025

Technology

Inimmune technology focuses on the discovery, optimization, and development of new immunomodulatory therapeutics for the treatment or prevention of allergy, autoimmunity, upper respiratory tract infections, and cancer, by targeting innate immune receptors.

Allergy
URT Infections
Antibiotics
Cancer
Autoimmunity

Inimmune is a promising new biotechnology company founded by pharmaceutical industry veterans, focused on developing the next generation of vaccines and immunotherapeutics.

Facebook-f Twitter Linkedin

Quick Links

Contact

  • 1121 E Broadway St, Ste 106, Missoula, MT, 59802
  • 406-541-5913
  • info@inimmune.com

© Copyright 2022 Inimmune. All Rights Reserved.

Website Design by Digital Marketing Missoula

Upper Respiratory Tract Infections

Inimmune is developing immunomodulators to induce broad antiviral innate immunity for the reduction of viral URT and associated exacerbations in asthma and COPD patients.
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.
Read More
Go

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
Read More
Go
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.
Read More
Go

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.
Read More
Go

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
Read More
Go
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Read More
Go
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.
Read More
Go

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
Read More
Go
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.
Read More
Go

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.
Read More
Go

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
Read More
Go
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Read More
Go
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.
Read More
Go

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
Read More
Go
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.
Read More
Go

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.
Read More
Go

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
Read More
Go
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Read More
Go
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.
Read More
Go

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
Read More
Go
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.
Read More
Go

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.
Read More
Go

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
Read More
Go
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Read More
Go
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.
Read More
Go

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
Read More
Go
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.
Read More
Go

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.
Read More
Go

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
Read More
Go
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Read More
Go
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.
Read More
Go

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
Read More
Go
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.
Read More
Go

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.
Read More
Go

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
Read More
Go
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Read More
Go

TLR-7/8 (INI-4001), TLR-4 (INI-2002), CTLR (UM-1098), STING